Trials / Completed
CompletedNCT00519233
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
A Phase I Investigation of the Intravenous Administration of AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of AGS-1C4D4 in patients with advanced HRPC.
Detailed description
Cohorts of 1-6 patients will be administered AGS-1C404 in sequentially rising dose levels. Dose escalation will continue until the MTD of AGS-1C4D4 is established or the maximum planned dose is reached.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGS-1C4D4 | IV |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2007-08-22
- Last updated
- 2014-05-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00519233. Inclusion in this directory is not an endorsement.